CymaBay Pipeline

Home / Pipeline

Overview

Our pipeline is focused on developing therapies for liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC) and NonAlcoholic SteatoHepatitis (NASH). Additionally, we have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.

  Pre-Clinical Phase 1 Phase 2 Phase 3
Internal Programs
Seladelpar
Primary Biliary Cholangitis
Seladelpar
Non-alcoholic Steatohepatitis
MBX-2982

(GPR 119 agonist)

Gut/Liver
CB-001

(GPR 120 agonist)

Gut/Liver